Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Core Insights - Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases [3] - The company will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference from March 10 to 12, 2025 [1] - Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia [3] Presentation Details - The presentation is scheduled for March 10, 2025, from 3:40 to 4:10 PM EST [2] - A webcast link for the presentation is provided, and a replay will be available for 30 days on the company's website [2] Company Overview - Larimar Therapeutics is developing an intracellular delivery platform to design fusion proteins targeting rare diseases characterized by deficiencies in intracellular bioactive compounds [3] - For more information, the company’s website is available at https://larimartx.com [3]